Survival outcomes in patients with human epidermal growth factor receptor 2 positive metastatic breast cancer administered a therapy following trastuzumab emtansine treatment.

MLA

Watanuki, Rurina, et al. “Survival Outcomes in Patients with Human Epidermal Growth Factor Receptor 2 Positive Metastatic Breast Cancer Administered a Therapy Following Trastuzumab Emtansine Treatment.” Medicine, vol. 99, no. 38, Sept. 2020, p. e22331. EBSCOhost, https://doi.org/10.1097/MD.0000000000022331.

APA

Watanuki, R., Shimomura, A., Yazaki, S., Noda-Narita, S., Sumiyoshi-Okuma, H., Nishikawa, T., Tanioka, M., Sudo, K., Shimoi, T., Noguchi, E., Yonemori, K., & Tamura, K. (2020). Survival outcomes in patients with human epidermal growth factor receptor 2 positive metastatic breast cancer administered a therapy following trastuzumab emtansine treatment. Medicine, 99(38), e22331. https://doi.org/10.1097/MD.0000000000022331

Chicago

Watanuki, Rurina, Akihiko Shimomura, Shu Yazaki, Shoko Noda-Narita, Hitomi Sumiyoshi-Okuma, Tadaaki Nishikawa, Maki Tanioka, et al. 2020. “Survival Outcomes in Patients with Human Epidermal Growth Factor Receptor 2 Positive Metastatic Breast Cancer Administered a Therapy Following Trastuzumab Emtansine Treatment.” Medicine 99 (38): e22331. doi:10.1097/MD.0000000000022331.